ID   UD11_HUMAN              Reviewed;         533 AA.
AC   P22309; A6NJC3; B8K286;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=UDP-glucuronosyltransferase 1-1;
DE            Short=UDPGT 1-1;
DE            Short=UGT1*1;
DE            Short=UGT1-01;
DE            Short=UGT1.1;
DE            EC=2.4.1.17;
DE   AltName: Full=Bilirubin-specific UDPGT isozyme 1;
DE            Short=hUG-BR1;
DE   AltName: Full=UDP-glucuronosyltransferase 1-A;
DE            Short=UGT-1A;
DE            Short=UGT1A;
DE   AltName: Full=UDP-glucuronosyltransferase 1A1;
DE   Flags: Precursor;
GN   Name=UGT1A1; Synonyms=GNT1, UGT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=1898728;
RA   Ritter J.K., Crawford J.M., Owens I.S.;
RT   "Cloning of two human liver bilirubin UDP-glucuronosyltransferase
RT   cDNAs with expression in COS-1 cells.";
RL   J. Biol. Chem. 266:1043-1047(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=1339448;
RA   Ritter J.K., Chen F., Sheen Y.Y., Tran H.M., Kimura S., Yeatman M.T.,
RA   Owens I.S.;
RT   "A novel complex locus UGT1 encodes human bilirubin, phenol, and other
RT   UDP-glucuronosyltransferase isozymes with identical carboxyl
RT   termini.";
RL   J. Biol. Chem. 267:3257-3261(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11434514; DOI=10.1097/00008571-200106000-00011;
RA   Gong Q.H., Cho J.W., Huang T., Potter C., Gholami N., Basu N.K.,
RA   Kubota S., Carvalho S., Pennington M.W., Owens I.S., Popescu N.C.;
RT   "Thirteen UDP-glucuronosyltransferase genes are encoded at the human
RT   UGT1 gene complex locus.";
RL   Pharmacogenetics 11:357-368(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Guillemette C., Levesque E., Girard H., Bernard O.;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-50.
RA   Ueyama H., Koiwai O., Soeda Y., Sato H., Satoh Y., Ohkubo I.,
RA   Doida Y.;
RT   "Analysis of the promoter of human bilirubin UDP-
RT   glucuronosyltransferase gene (UGT1*1) in relevance to Gilbert's
RT   syndrome.";
RL   Hepatol. Res. 9:152-163(1997).
RN   [7]
RP   COMPONENT OF A CHAPERONE COMPLEX.
RX   PubMed=12475965; DOI=10.1091/mbc.E02-05-0311;
RA   Meunier L., Usherwood Y.-K., Chung K.T., Hendershot L.M.;
RT   "A subset of chaperones and folding enzymes form multiprotein
RT   complexes in endoplasmic reticulum to bind nascent proteins.";
RL   Mol. Biol. Cell 13:4456-4469(2002).
RN   [8]
RP   ALTERNATIVE SPLICING, FUNCTION (ISOFORM 2), SUBCELLULAR LOCATION,
RP   SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=17187418; DOI=10.1002/hep.21464;
RA   Levesque E., Girard H., Journault K., Lepine J., Guillemette C.;
RT   "Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a new
RT   splicing event at the UGT1A locus.";
RL   Hepatology 45:128-138(2007).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, KINETIC PARAMETERS, SUBSTRATE
RP   SPECIFICITY, AND CHARACTERIZATION OF VARIANTS CN2 ARG-71; LEU-83;
RP   GLN-229 AND ASP-486.
RX   PubMed=18004206; DOI=10.1097/FPC.0b013e328256b1b6;
RA   Udomuksorn W., Elliot D.J., Lewis B.C., Mackenzie P.I.,
RA   Yoovathaworn K., Miners J.O.;
RT   "Influence of mutations associated with Gilbert and Crigler-Najjar
RT   type II syndromes on the glucuronidation kinetics of bilirubin and
RT   other UDP-glucuronosyltransferase 1A substrates.";
RL   Pharmacogenet. Genomics 17:1017-1029(2007).
RN   [10]
RP   ALTERNATIVE SPLICING, CATALYTIC ACTIVITY, FUNCTION (ISOFORM 2), AND
RP   TISSUE SPECIFICITY.
RX   PubMed=18004212; DOI=10.1097/FPC.0b013e3282f1f118;
RA   Girard H., Levesque E., Bellemare J., Journault K., Caillier B.,
RA   Guillemette C.;
RT   "Genetic diversity at the UGT1 locus is amplified by a novel 3'
RT   alternative splicing mechanism leading to nine additional UGT1A
RT   proteins that act as regulators of glucuronidation activity.";
RL   Pharmacogenet. Genomics 17:1077-1089(2007).
RN   [11]
RP   FUNCTION.
RX   PubMed=19545173; DOI=10.1021/mp8002557;
RA   Tang L., Singh R., Liu Z., Hu M.;
RT   "Structure and concentration changes affect characterization of UGT
RT   isoform-specific metabolism of isoflavones.";
RL   Mol. Pharm. 6:1466-1482(2009).
RN   [12]
RP   FUNCTION, SUBSTRATE SPECIFICITY, VARIANT CN1 THR-402, VARIANTS CN2
RP   ARG-15; ARG-71; PHE-191; TRP-209; TRP-336; HIS-387; PRO-443 AND
RP   ASP-486, CHARACTERIZATION OF VARIANT CN1 THR-402, AND CHARACTERIZATION
RP   OF VARIANTS CN2 ARG-71; GLN-175; PHE-191; TRP-209; ARG-331; TRP-336;
RP   HIS-387; VAL-395 AND PRO-443.
RX   PubMed=19830808; DOI=10.1002/humu.21133;
RA   Sneitz N., Bakker C.T., de Knegt R.J., Halley D.J., Finel M.,
RA   Bosma P.J.;
RT   "Crigler-Najjar syndrome in The Netherlands: identification of four
RT   novel UGT1A1 alleles, genotype-phenotype correlation, and functional
RT   analysis of 10 missense mutants.";
RL   Hum. Mutat. 31:52-59(2010).
RN   [13]
RP   INVOLVEMENT IN BILIQTL1.
RX   PubMed=19414484; DOI=10.1093/hmg/ddp202;
RA   Johnson A.D., Kavousi M., Smith A.V., Chen M.H., Dehghan A.,
RA   Aspelund T., Lin J.P., van Duijn C.M., Harris T.B., Cupples L.A.,
RA   Uitterlinden A.G., Launer L., Hofman A., Rivadeneira F., Stricker B.,
RA   Yang Q., O'Donnell C.J., Gudnason V., Witteman J.C.;
RT   "Genome-wide association meta-analysis for total serum bilirubin
RT   levels.";
RL   Hum. Mol. Genet. 18:2700-2710(2009).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-102.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   SUBUNIT.
RX   PubMed=20610558; DOI=10.1124/dmd.110.034835;
RA   Bellemare J., Rouleau M., Girard H., Harvey M., Guillemette C.;
RT   "Alternatively spliced products of the UGT1A gene interact with the
RT   enzymatically active proteins to inhibit glucuronosyltransferase
RT   activity in vitro.";
RL   Drug Metab. Dispos. 38:1785-1789(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   VARIANT CN1 PHE-375.
RX   PubMed=1634050;
RA   Bosma P.J., Chowdhury J.R., Huang T.-J., Lahiri P., Elferink R.P.J.O.,
RA   van Es H.H.G., Lederstein M., Whitington P.F., Jansen P.L.M.,
RA   Chowdhury N.R.;
RT   "Mechanisms of inherited deficiencies of multiple UDP-
RT   glucuronosyltransferase isoforms in two patients with Crigler-Najjar
RT   syndrome, type I.";
RL   FASEB J. 6:2859-2863(1992).
RN   [18]
RP   VARIANTS CN2 ARG-71 AND ASP-486.
RX   PubMed=8280139; DOI=10.1006/bbrc.1993.2610;
RA   Aono S., Yamada Y., Keino H., Hanada N., Nakagawa T., Sasaoka Y.,
RA   Yazawa T., Sato H., Koiwai O.;
RT   "Identification of defect in the genes for bilirubin UDP-glucuronosyl-
RT   transferase in a patient with Crigler-Najjar syndrome type II.";
RL   Biochem. Biophys. Res. Commun. 197:1239-1244(1993).
RN   [19]
RP   VARIANT CN2 ARG-331.
RX   PubMed=8276413; DOI=10.1006/geno.1993.1451;
RA   Moghrabi N., Clarke D.J., Boxer M., Burchell B.;
RT   "Identification of an A-to-G missense mutation in exon 2 of the UGT1
RT   gene complex that causes Crigler-Najjar syndrome type 2.";
RL   Genomics 18:171-173(1993).
RN   [20]
RP   VARIANT CN1 PHE-170 DEL.
RX   PubMed=8226884;
RA   Ritter J.K., Yeatman M.T., Kaiser C., Gridelli B., Owens I.S.;
RT   "A phenylalanine codon deletion at the UGT1 gene complex locus of a
RT   Crigler-Najjar type I patient generates a pH-sensitive bilirubin UDP-
RT   glucuronosyltransferase.";
RL   J. Biol. Chem. 268:23573-23579(1993).
RN   [21]
RP   VARIANTS CN1 VAL-292; GLU-308; ARG-357; THR-368; ARG-381; PRO-401 AND
RP   GLU-428.
RX   PubMed=7989045; DOI=10.1007/BF00206965;
RA   Labrune P., Myara A., Hadchouel M., Ronchi F., Bernard O., Trivin F.,
RA   Roy Chowdhury N., Roy Chowdhury J., Munnich A., Odievre M.;
RT   "Genetic heterogeneity of Crigler-Najjar syndrome type I: a study of
RT   14 cases.";
RL   Hum. Genet. 94:693-697(1994).
RN   [22]
RP   VARIANTS CN1 GLU-308 AND PHE-375, AND CHARACTERIZATION OF VARIANTS CN1
RP   GLU-308 AND PHE-375.
RX   PubMed=7906695; DOI=10.1172/JCI117008;
RA   Erps L.T., Ritter J.K., Hersh J.H., Blossom D., Martin N.C.,
RA   Owens I.S.;
RT   "Identification of two single base substitutions in the UGT1 gene
RT   locus which abolish bilirubin uridine diphosphate
RT   glucuronosyltransferase activity in vitro.";
RL   J. Clin. Invest. 93:564-570(1994).
RN   [23]
RP   VARIANTS CN1 PHE-170 DEL; ARG-177; ARG-276 AND PHE-375, AND VARIANTS
RP   CN2 GLN-175 AND TRP-209.
RX   PubMed=7989595; DOI=10.1172/JCI117604;
RA   Seppen J., Bosma P.J., Goldhoorn B.G., Bakker C.T.M.,
RA   Roy Chowdhury J., Roy Chowdhury N., Jansen P.L.M.,
RA   Oude Elferink R.P.J.;
RT   "Discrimination between Crigler-Najjar type I and II by expression of
RT   mutant bilirubin uridine diphosphate-glucuronosyltransferase.";
RL   J. Clin. Invest. 94:2385-2391(1994).
RN   [24]
RP   VARIANTS GILBS ARG-71; GLN-229 AND GLY-367.
RC   TISSUE=Liver, and Peripheral blood leukocyte;
RX   PubMed=7715297; DOI=10.1016/S0140-6736(95)90702-5;
RA   Aono S., Adachi Y., Uyama E., Yamada Y., Keino H., Nanno T.,
RA   Koiwai O., Sato H.;
RT   "Analysis of genes for bilirubin UDP-glucuronosyltransferase in
RT   Gilbert's syndrome.";
RL   Lancet 345:958-959(1995).
RN   [25]
RP   VARIANT CN2 ARG-15, AND CHARACTERIZATION OF VARIANT CN2 ARG-15.
RX   PubMed=8706880; DOI=10.1016/0014-5793(96)00677-1;
RA   Seppen J., Steenken E., Lindhout D., Bosma P.J., Oude Elferink R.P.J.;
RT   "A mutation which disrupts the hydrophobic core of the signal peptide
RT   of bilirubin UDP-glucuronosyltransferase, an endoplasmic reticulum
RT   membrane protein, causes Crigler-Najjar type II.";
RL   FEBS Lett. 390:294-298(1996).
RN   [26]
RP   VARIANT CN2 THR-294, AND CHARACTERIZATION OF VARIANT CN2 THR-294.
RX   PubMed=9639672; DOI=10.1016/S0925-4439(98)00030-1;
RA   Ciotti M., Chen F., Rubaltelli F.F., Owens I.S.;
RT   "Coding defect and a TATA box mutation at the bilirubin UDP-
RT   glucuronosyltransferase gene cause Crigler-Najjar type I disease.";
RL   Biochim. Biophys. Acta 1407:40-50(1998).
RN   [27]
RP   VARIANTS CN2 ARG-71; TRP-209; GLN-229 AND ASP-486.
RX   PubMed=9621515; DOI=10.1007/s100380050050;
RA   Yamamoto K., Soeda Y., Kamisako T., Hosaka H., Fukano M., Sato H.,
RA   Fujiyama Y., Dachi Y., Satoh Y., Bamba T.;
RT   "Analysis of bilirubin uridine 5'-diphosphate (UDP)-
RT   glucuronosyltransferase gene mutations in seven patients with Crigler-
RT   Najjar syndrome type II.";
RL   J. Hum. Genet. 43:111-114(1998).
RN   [28]
RP   VARIANT GILBS ASP-486.
RX   PubMed=9627603; DOI=10.1016/S0022-3476(98)70408-1;
RA   Maruo Y., Sato H., Yamano T., Doida Y., Shimada M.;
RT   "Gilbert syndrome caused by a homozygous missense mutation (Tyr486Asp)
RT   of bilirubin UDP-glucuronosyltransferase gene.";
RL   J. Pediatr. 132:1045-1047(1998).
RN   [29]
RP   VARIANTS CN1 ASP-39; PHE-170 DEL; ARG-177; ARG-276; VAL-291; GLU-308;
RP   TRP-336; ARG-357; THR-368; PHE-375; ARG-381; SER-387; PRO-401 AND
RP   GLU-428, VARIANTS CN2 ARG-15; GLN-175; TRP-209; GLY-225 AND ARG-331,
RP   AND VARIANTS GILBS ARG-71; GLN-229; THR-294; GLY-367 AND ASP-486.
RX   PubMed=11013440;
RX   DOI=10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z;
RA   Kadakol A., Ghosh S.S., Sappal B.S., Sharma G., Chowdhury J.R.,
RA   Chowdhury N.R.;
RT   "Genetic lesions of bilirubin uridine-diphosphoglucuronate
RT   glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert
RT   syndromes: correlation of genotype to phenotype.";
RL   Hum. Mutat. 16:297-306(2000).
RN   [30]
RP   VARIANTS HBLRTFN ARG-71 AND ASP-486.
RX   PubMed=11061796; DOI=10.1542/peds.106.5.e59;
RA   Maruo Y., Nishizawa K., Sato H., Sawa H., Shimada M.;
RT   "Prolonged unconjugated hyperbilirubinemia associated with breast milk
RT   and mutations of the bilirubin uridine diphosphate-
RT   glucuronosyltransferase gene.";
RL   Pediatrics 106:E59-E59(2000).
RN   [31]
RP   VARIANT CN2 GLN-175.
RX   PubMed=11370628; DOI=10.1136/jmg.38.4.244;
RA   Kadakol A., Sappal B.S., Ghosh S.S., Lowenheim M., Chowdhury A.,
RA   Chowdhury S., Santra A., Arias I.M., Chowdhury J.R., Chowdhury N.R.;
RT   "Interaction of coding region mutations and the Gilbert-type promoter
RT   abnormality of the UGT1A1 gene causes moderate degrees of unconjugated
RT   hyperbilirubinaemia and may lead to neonatal kernicterus.";
RL   J. Med. Genet. 38:244-249(2001).
RN   [32]
RP   VARIANT CN2 ASP-400.
RX   PubMed=12402338; DOI=10.1002/humu.10122;
RA   Labrune P., Myara A., Chalas J., Le Bihan B., Capel L., Francoual J.;
RT   "Association of a homozygous (TA)8 promoter polymorphism and a N400D
RT   mutation of UGT1A1 in a child with Crigler-Najjar type II syndrome.";
RL   Hum. Mutat. 20:399-401(2002).
RN   [33]
RP   VARIANT GILBS LEU-83.
RX   PubMed=12139570; DOI=10.1046/j.1442-200X.2002.t01-1-01577.x;
RA   Sutomo R., Laosombat V., Sadewa A.H., Yokoyama N., Nakamura H.,
RA   Matsuo M., Nishio H.;
RT   "Novel missense mutation of the UGT1A1 gene in Thai siblings with
RT   Gilbert's syndrome.";
RL   Pediatr. Int. 44:427-432(2002).
RN   [34]
RP   CHARACTERIZATION OF VARIANT CN2 ARG-15.
RX   PubMed=14550264; DOI=10.1016/j.bbrc.2003.09.072;
RA   Ohnishi A., Emi Y.;
RT   "Rapid proteasomal degradation of translocation-deficient UDP-
RT   glucuronosyltransferase 1A1 proteins in patients with Crigler-Najjar
RT   type II.";
RL   Biochem. Biophys. Res. Commun. 310:735-741(2003).
RN   [35]
RP   VARIANTS CN1 GLN-336; ARG-357; PHE-375; SER-387 AND VAL-395, VARIANTS
RP   CN2 GLN-34; PHE-170 DEL; TRP-209; GLY-225; LEU-336; TRP-336; ARG-354;
RP   CYS-403 AND ASP-478, AND VARIANTS CN1/CN2 VAL-377 AND ARG-461.
RX   PubMed=15712364; DOI=10.1002/humu.9322;
RA   Servedio V., d'Apolito M., Maiorano N., Minuti B., Torricelli F.,
RA   Ronchi F., Zancan L., Perrotta S., Vajro P., Boschetto L.,
RA   Iolascon A.;
RT   "Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome
RT   patients: identification of twelve novel alleles and genotype-
RT   phenotype correlation.";
RL   Hum. Mutat. 25:325-325(2005).
RN   [36]
RP   VARIANT CN1 PHE-171 DEL, AND VARIANTS CN2 TYR-279; ARG-354; VAL-370;
RP   VAL-395; PRO-443 AND ARG-461.
RX   PubMed=17229650; DOI=10.3324/haematol.10585;
RA   D'Apolito M., Marrone A., Servedio V., Vajro P., De Falco L.,
RA   Iolascon A.;
RT   "Seven novel mutations of the UGT1A1 gene in patients with
RT   unconjugated hyperbilirubinemia.";
RL   Haematologica 92:133-134(2007).
RN   [37]
RP   VARIANT CN1 ASN-36, AND VARIANT CN2 CYS-230.
RX   PubMed=23992562; DOI=10.1111/ahg.12039;
RA   Khan S., Irfan M., Sher G., Zubaida B., Alvi M.A., Yasinzai M.,
RA   Naeem M.;
RT   "UGT1A1 gene mutations in Pakistani children suffering from inherited
RT   nonhemolytic unconjugated hyperbilirubinemias.";
RL   Ann. Hum. Genet. 77:482-487(2013).
RN   [38]
RP   VARIANTS CN2 PHE-170 DEL AND CYS-367.
RX   PubMed=23099197; DOI=10.1016/j.clinbiochem.2012.10.007;
RA   Minucci A., Canu G., Gentile L., Cimino V., Giardina B., Zuppi C.,
RA   Capoluongo E.;
RT   "Identification of a novel mutation in UDP-glucuronosyltransferase
RT   (UGT1A1) gene in a child with neonatal unconjugated
RT   hyperbilirubinemia.";
RL   Clin. Biochem. 46:170-172(2013).
CC   -!- FUNCTION: UDPGT is of major importance in the conjugation and
CC       subsequent elimination of potentially toxic xenobiotics and
CC       endogenous compounds. This isoform glucuronidates bilirubin IX-
CC       alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates
CC       and diconjugate. Is also able to catalyze the glucuronidation of
CC       17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-
CC       methylumbelliferone, 1-naphthol, paranitrophenol, scopoletin, and
CC       umbelliferone. Isoform 2 lacks transferase activity but acts as a
CC       negative regulator of isoform 1. {ECO:0000269|PubMed:18004206,
CC       ECO:0000269|PubMed:19545173, ECO:0000269|PubMed:19830808}.
CC   -!- CATALYTIC ACTIVITY: UDP-glucuronate + acceptor = UDP + acceptor
CC       beta-D-glucuronoside. {ECO:0000269|PubMed:18004206,
CC       ECO:0000269|PubMed:18004212}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.26 uM for bilirubin {ECO:0000269|PubMed:18004206};
CC         Vmax=1080 pmol/min/mg enzyme with bilirubin as substrate
CC         {ECO:0000269|PubMed:18004206};
CC   -!- SUBUNIT: Isoform 1 interacts with isoform 2/i2 suggesting that
CC       oligomerization is involved in negative regulation of transferase
CC       activity by isoform 2. Isoform 1 also interacts with respective i2
CC       isoforms of UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9 and
CC       UGT1A10. Part of a large chaperone multiprotein complex comprising
CC       DNAJB11, HSP90B1, HSPA5, HYOU, PDIA2, PDIA4, PDIA6, PPIB, SDF2L1,
CC       UGT1A1 and very small amounts of ERP29, but not, or at very low
CC       levels, CALR nor CANX. {ECO:0000269|PubMed:17187418,
CC       ECO:0000269|PubMed:20610558}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Microsome
CC       {ECO:0000269|PubMed:17187418}. Endoplasmic reticulum membrane
CC       {ECO:0000305|PubMed:17187418}; Single-pass membrane protein
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Microsome
CC       {ECO:0000269|PubMed:17187418}. Endoplasmic reticulum
CC       {ECO:0000305|PubMed:17187418}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=i1;
CC         IsoId=P22309-1; Sequence=Displayed;
CC       Name=2; Synonyms=i2, UGT1A1s;
CC         IsoId=P22309-2; Sequence=VSP_053958;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in
CC       liver, colon and small intestine. Isoform 2 but not isoform 1 is
CC       expressed in kidney. Isoform 1 and isoform 2 are not expressed in
CC       esophagus. Not expressed in skin. {ECO:0000269|PubMed:1339448,
CC       ECO:0000269|PubMed:17187418, ECO:0000269|PubMed:18004212}.
CC   -!- POLYMORPHISM: Genetic variation in UGT1A1 defines the bilirubin
CC       serum levels quantitative trait locus 1 (BILIQTL1) [MIM:601816].
CC       Variation in serum bilirubin is associated with altered
CC       cardiovascular disease risk and drug metabolism.
CC       {ECO:0000269|PubMed:19414484}.
CC   -!- DISEASE: Gilbert syndrome (GILBS) [MIM:143500]: Occurs as a
CC       consequence of reduced bilirubin transferase activity and is often
CC       detected in young adults with vague non-specific complaints.
CC       {ECO:0000269|PubMed:11013440, ECO:0000269|PubMed:12139570,
CC       ECO:0000269|PubMed:7715297, ECO:0000269|PubMed:9627603}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Transient familial neonatal hyperbilirubinemia (HBLRTFN)
CC       [MIM:237900]: A condition characterized by excessive concentration
CC       of bilirubin in the blood, which may lead to jaundice. Breast milk
CC       jaundice is a common problem in nursing infants.
CC       {ECO:0000269|PubMed:11061796}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry. The defect
CC       has been ascribed to various breast milk substances, but the
CC       component or combination of components that is responsible remains
CC       unclear. Defects of UGT1A1 are an underlying cause of the
CC       prolonged unconjugated hyperbilirubinemia associated with breast
CC       milk. One or more components in the milk may trigger the jaundice
CC       in infants who have such mutations. Mutations are identical to
CC       those detected in patients with Gilbert syndrome, a risk factor of
CC       neonatal non-physiologic hyperbilirubinemia and a genetic factor
CC       in fasting hyperbilirubinemia.
CC   -!- DISEASE: Crigler-Najjar syndrome 1 (CN1) [MIM:218800]: Patients
CC       have severe hyperbilirubinemia and usually die of kernicterus
CC       (bilirubin accumulation in the basal ganglia and brainstem nuclei)
CC       within the first year of life. CN1 inheritance is autosomal
CC       recessive. {ECO:0000269|PubMed:11013440,
CC       ECO:0000269|PubMed:15712364, ECO:0000269|PubMed:1634050,
CC       ECO:0000269|PubMed:17229650, ECO:0000269|PubMed:19830808,
CC       ECO:0000269|PubMed:23992562, ECO:0000269|PubMed:7906695,
CC       ECO:0000269|PubMed:7989045, ECO:0000269|PubMed:7989595,
CC       ECO:0000269|PubMed:8226884}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Crigler-Najjar syndrome 2 (CN2) [MIM:606785]: Patients
CC       have less severe hyperbilirubinemia and usually survive into
CC       adulthood without neurologic damage. Phenobarbital, which induces
CC       the partially deficient glucuronyl transferase, can diminish the
CC       jaundice. CN2 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:11013440, ECO:0000269|PubMed:11370628,
CC       ECO:0000269|PubMed:12402338, ECO:0000269|PubMed:14550264,
CC       ECO:0000269|PubMed:15712364, ECO:0000269|PubMed:17229650,
CC       ECO:0000269|PubMed:18004206, ECO:0000269|PubMed:19830808,
CC       ECO:0000269|PubMed:23099197, ECO:0000269|PubMed:23992562,
CC       ECO:0000269|PubMed:7989595, ECO:0000269|PubMed:8276413,
CC       ECO:0000269|PubMed:8280139, ECO:0000269|PubMed:8706880,
CC       ECO:0000269|PubMed:9621515, ECO:0000269|PubMed:9639672}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: The gene is part of the UGT1A complex locus which
CC       displays alternative use of promoters, first exons and terminal
CC       exons. The locus is defined by 13 first exons, which are
CC       alternatively spliced to 3 other common exons and 2 alternative
CC       terminal exons 5. From the 27 possible mRNA isoforms, 9 produce
CC       functionally active polypeptides (UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7,
CC       1A8, 1A9 and 1A10) called isoforms 1 (i1). Use of an alternative
CC       exon 5 (5b) as terminal exon is leading to 9 additional
CC       alternatively spliced products termed isoforms i2 and which lack
CC       transferase activity.
CC   -!- SIMILARITY: Belongs to the UDP-glycosyltransferase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA61247.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAF03522.2; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Glucuronosyltransferase entry;
CC       URL="https://en.wikipedia.org/wiki/Glucuronosyltransferase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M57899; AAA63195.1; -; mRNA.
DR   EMBL; M84124; AAA61247.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M84122; AAA61247.1; JOINED; Genomic_DNA.
DR   EMBL; M84123; AAA61247.1; JOINED; Genomic_DNA.
DR   EMBL; M84125; AAA61248.1; -; Genomic_DNA.
DR   EMBL; DQ364247; ABC96771.1; -; mRNA.
DR   EMBL; AF297093; AAG30424.1; -; Genomic_DNA.
DR   EMBL; AC006985; AAF03522.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; D87674; BAA25600.1; -; Genomic_DNA.
DR   CCDS; CCDS2510.1; -. [P22309-1]
DR   PIR; A39092; A39092.
DR   RefSeq; NP_000454.1; NM_000463.2. [P22309-1]
DR   UniGene; Hs.554822; -.
DR   ProteinModelPortal; P22309; -.
DR   BioGrid; 120087; 4.
DR   IntAct; P22309; 9.
DR   STRING; 9606.ENSP00000304845; -.
DR   BindingDB; P22309; -.
DR   ChEMBL; CHEMBL1287617; -.
DR   DrugBank; DB01048; Abacavir.
DR   DrugBank; DB00316; Acetaminophen.
DR   DrugBank; DB00173; Adenine.
DR   DrugBank; DB01076; Atorvastatin.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB08930; Dolutegravir.
DR   DrugBank; DB06210; Eltrombopag.
DR   DrugBank; DB00530; Erlotinib.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB00773; Etoposide.
DR   DrugBank; DB00973; Ezetimibe.
DR   DrugBank; DB04953; Ezogabine.
DR   DrugBank; DB01544; Flunitrazepam.
DR   DrugBank; DB00712; Flurbiprofen.
DR   DrugBank; DB01095; Fluvastatin.
DR   DrugBank; DB06741; Gavestinel.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB05039; Indacaterol.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB00762; Irinotecan.
DR   DrugBank; DB00678; Losartan.
DR   DrugBank; DB00227; Lovastatin.
DR   DrugBank; DB00295; Morphine.
DR   DrugBank; DB00688; Mycophenolate mofetil.
DR   DrugBank; DB01024; Mycophenolic acid.
DR   DrugBank; DB00704; Naltrexone.
DR   DrugBank; DB00788; Naproxen.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB06817; Raltegravir.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB01045; Rifampicin.
DR   DrugBank; DB00641; Simvastatin.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB00870; Suprofen.
DR   DrugBank; DB01420; Testosterone Propionate.
DR   DrugBank; DB00197; Troglitazone.
DR   CAZy; GT1; Glycosyltransferase Family 1.
DR   iPTMnet; P22309; -.
DR   PhosphoSitePlus; P22309; -.
DR   BioMuta; UGT1A1; -.
DR   DMDM; 136729; -.
DR   PaxDb; P22309; -.
DR   PeptideAtlas; P22309; -.
DR   PRIDE; P22309; -.
DR   DNASU; 54658; -.
DR   Ensembl; ENST00000305208; ENSP00000304845; ENSG00000241635. [P22309-1]
DR   Ensembl; ENST00000360418; ENSP00000353593; ENSG00000241635. [P22309-2]
DR   GeneID; 54658; -.
DR   KEGG; hsa:54658; -.
DR   CTD; 54658; -.
DR   DisGeNET; 54658; -.
DR   GeneCards; UGT1A1; -.
DR   HGNC; HGNC:12530; UGT1A1.
DR   MalaCards; UGT1A1; -.
DR   MIM; 143500; phenotype.
DR   MIM; 191740; gene.
DR   MIM; 218800; phenotype.
DR   MIM; 237900; phenotype.
DR   MIM; 601816; phenotype.
DR   MIM; 606785; phenotype.
DR   neXtProt; NX_P22309; -.
DR   OpenTargets; ENSG00000241635; -.
DR   Orphanet; 79234; Crigler-Najjar syndrome type 1.
DR   Orphanet; 79235; Crigler-Najjar syndrome type 2.
DR   Orphanet; 357; Gilbert syndrome.
DR   Orphanet; 240885; Irinotecan toxicity.
DR   Orphanet; 240905; Raltegravir toxicity.
DR   Orphanet; 2312; Transient familial neonatal hyperbilirubinemia.
DR   PharmGKB; PA37181; -.
DR   PharmGKB; PA420; -.
DR   eggNOG; KOG1192; Eukaryota.
DR   eggNOG; COG1819; LUCA.
DR   GeneTree; ENSGT00760000118949; -.
DR   HOGENOM; HOG000220832; -.
DR   HOVERGEN; HBG004033; -.
DR   InParanoid; P22309; -.
DR   KO; K00699; -.
DR   OMA; LEESHFD; -.
DR   OrthoDB; EOG091G06JC; -.
DR   PhylomeDB; P22309; -.
DR   TreeFam; TF315472; -.
DR   BRENDA; 2.4.1.17; 2681.
DR   BRENDA; 2.4.1.95; 2681.
DR   Reactome; R-HSA-156588; Glucuronidation.
DR   Reactome; R-HSA-189483; Heme degradation.
DR   SABIO-RK; P22309; -.
DR   GenomeRNAi; 54658; -.
DR   PRO; PR:P22309; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000241635; -.
DR   CleanEx; HS_UGT1A1; -.
DR   ExpressionAtlas; P22309; baseline and differential.
DR   Genevisible; P22309; HS.
DR   GO; GO:0070069; C:cytochrome complex; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0034663; C:endoplasmic reticulum chaperone complex; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; NAS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0004857; F:enzyme inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0015020; F:glucuronosyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0001972; F:retinoic acid binding; IDA:BHF-UCL.
DR   GO; GO:0005496; F:steroid binding; IDA:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; IEA:Ensembl.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0006789; P:bilirubin conjugation; TAS:Reactome.
DR   GO; GO:0070980; P:biphenyl catabolic process; IEA:Ensembl.
DR   GO; GO:0052695; P:cellular glucuronidation; IDA:UniProtKB.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0007586; P:digestion; NAS:ProtInc.
DR   GO; GO:0017144; P:drug metabolic process; IC:BHF-UCL.
DR   GO; GO:0008210; P:estrogen metabolic process; TAS:ProtInc.
DR   GO; GO:0051552; P:flavone metabolic process; IDA:BHF-UCL.
DR   GO; GO:0052696; P:flavonoid glucuronidation; IDA:BHF-UCL.
DR   GO; GO:0042167; P:heme catabolic process; TAS:Reactome.
DR   GO; GO:0046483; P:heterocycle metabolic process; IC:BHF-UCL.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:2001030; P:negative regulation of cellular glucuronidation; IDA:UniProtKB.
DR   GO; GO:0045922; P:negative regulation of fatty acid metabolic process; ISS:BHF-UCL.
DR   GO; GO:1904224; P:negative regulation of glucuronosyltransferase activity; ISS:BHF-UCL.
DR   GO; GO:0045939; P:negative regulation of steroid metabolic process; IC:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   GO; GO:0042573; P:retinoic acid metabolic process; IC:BHF-UCL.
DR   GO; GO:0008202; P:steroid metabolic process; IC:BHF-UCL.
DR   GO; GO:0052697; P:xenobiotic glucuronidation; IDA:BHF-UCL.
DR   InterPro; IPR002213; UDP_glucos_trans.
DR   PANTHER; PTHR11926; PTHR11926; 1.
DR   Pfam; PF00201; UDPGT; 1.
DR   PROSITE; PS00375; UDPGT; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Endoplasmic reticulum; Glycoprotein; Glycosyltransferase; Membrane;
KW   Microsome; Reference proteome; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    533       UDP-glucuronosyltransferase 1-1.
FT                                /FTId=PRO_0000036000.
FT   TRANSMEM    491    507       Helical. {ECO:0000255}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    295    295       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    347    347       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     435    533       SYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLR
FT                                PAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRK
FT                                CLGKKGRVKKAHKSKTH -> RKKQQSGRQM (in
FT                                isoform 2). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_053958.
FT   VARIANT      15     15       L -> R (in CN2; mutant protein rapidly
FT                                degraded by the proteasome owing to its
FT                                mislocalization in the cell;
FT                                dbSNP:rs111033541).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:14550264,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:8706880}.
FT                                /FTId=VAR_019410.
FT   VARIANT      34     34       P -> Q (in CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026134.
FT   VARIANT      36     36       D -> N (in CN1).
FT                                {ECO:0000269|PubMed:23992562}.
FT                                /FTId=VAR_071402.
FT   VARIANT      39     39       H -> D (in CN1; dbSNP:rs72551339).
FT                                {ECO:0000269|PubMed:11013440}.
FT                                /FTId=VAR_026135.
FT   VARIANT      71     71       G -> R (in CN2, GILBS and HBLRTFN; has
FT                                significant residual bilirubin
FT                                glucuronidation activity of about 25% to
FT                                50% of that of the wild-type protein;
FT                                displays no change in biluribin affinity;
FT                                dbSNP:rs4148323).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:11061796,
FT                                ECO:0000269|PubMed:18004206,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:7715297,
FT                                ECO:0000269|PubMed:8280139,
FT                                ECO:0000269|PubMed:9621515}.
FT                                /FTId=VAR_009504.
FT   VARIANT      83     83       F -> L (in GILBS; displays less than 10%
FT                                of wild-type bilirubin glucuronidation
FT                                activity; dbSNP:rs56059937).
FT                                {ECO:0000269|PubMed:12139570,
FT                                ECO:0000269|PubMed:18004206}.
FT                                /FTId=VAR_026136.
FT   VARIANT     170    170       Missing (in CN1 and CN2; has nearly
FT                                normal activity at pH 7.6 and is inactive
FT                                at pH 6.4). {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:23099197,
FT                                ECO:0000269|PubMed:7989595,
FT                                ECO:0000269|PubMed:8226884}.
FT                                /FTId=VAR_007695.
FT   VARIANT     171    171       Missing (in CN2).
FT                                {ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_064955.
FT   VARIANT     175    175       L -> Q (in CN2; has low residual
FT                                bilirubin glucuronidation activity of
FT                                about 4.6% of that of the wild-type
FT                                protein; dbSNP:rs72551341).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:11370628,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:7989595}.
FT                                /FTId=VAR_019411.
FT   VARIANT     177    177       C -> R (in CN1; dbSNP:rs72551342).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989595}.
FT                                /FTId=VAR_007697.
FT   VARIANT     191    191       S -> F (in CN2; has low residual
FT                                bilirubin glucuronidation activity of
FT                                about 5.3% of that of the wild-type
FT                                protein). {ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_064956.
FT   VARIANT     209    209       R -> W (in CN2; has low residual
FT                                bilirubin glucuronidation activity of
FT                                about 2.9% of that of the wild-type
FT                                protein; dbSNP:rs72551343).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:7989595,
FT                                ECO:0000269|PubMed:9621515}.
FT                                /FTId=VAR_007698.
FT   VARIANT     225    225       V -> G (in CN2; dbSNP:rs35003977).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026137.
FT   VARIANT     229    229       P -> Q (in CN2 and GILBS; displays 2-fold
FT                                decrease in biluribin affinity and 61% of
FT                                wild-type bilirubin glucuronidation
FT                                activity; dbSNP:rs35350960).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:18004206,
FT                                ECO:0000269|PubMed:7715297,
FT                                ECO:0000269|PubMed:9621515}.
FT                                /FTId=VAR_009505.
FT   VARIANT     230    230       Y -> C (in CN2; dbSNP:rs754922685).
FT                                {ECO:0000269|PubMed:23992562}.
FT                                /FTId=VAR_071403.
FT   VARIANT     276    276       G -> R (in CN1; dbSNP:rs72551345).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989595}.
FT                                /FTId=VAR_007699.
FT   VARIANT     279    279       N -> Y (in CN2; dbSNP:rs397978903).
FT                                {ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_064957.
FT   VARIANT     291    291       E -> V (in CN1).
FT                                {ECO:0000269|PubMed:11013440}.
FT                                /FTId=VAR_026138.
FT   VARIANT     292    292       A -> V (in CN1).
FT                                {ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007700.
FT   VARIANT     294    294       I -> T (in GILBS and CN2; 40-55% normal
FT                                activity; normal Km for bilirubin; when
FT                                homozygous far less repressive and
FT                                generates the mild Gilbert phenotype;
FT                                dbSNP:rs72551347).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:9639672}.
FT                                /FTId=VAR_026139.
FT   VARIANT     308    308       G -> E (in CN1; no enzyme activity;
FT                                dbSNP:rs62625011).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7906695,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007701.
FT   VARIANT     331    331       Q -> R (in CN2; has no residual bilirubin
FT                                glucuronidation activity;
FT                                dbSNP:rs72551348).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:8276413}.
FT                                /FTId=VAR_007702.
FT   VARIANT     336    336       R -> L (in CN1 and CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026140.
FT   VARIANT     336    336       R -> Q (in CN1; dbSNP:rs750453538).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026141.
FT   VARIANT     336    336       R -> W (in CN2; has very low residual
FT                                bilirubin glucuronidation activity of
FT                                about 0.4% of that of the wild-type
FT                                protein; dbSNP:rs139607673).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_026142.
FT   VARIANT     354    354       W -> R (in CN2).
FT                                {ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_026143.
FT   VARIANT     357    357       Q -> R (in CN1; dbSNP:rs72551351).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007703.
FT   VARIANT     367    367       R -> C (in CN2; dbSNP:rs55750087).
FT                                {ECO:0000269|PubMed:23099197}.
FT                                /FTId=VAR_071404.
FT   VARIANT     367    367       R -> G (in GILBS; dbSNP:rs55750087).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7715297}.
FT                                /FTId=VAR_012283.
FT   VARIANT     368    368       A -> T (in CN1; dbSNP:rs72551352).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007704.
FT   VARIANT     370    370       I -> V (in CN2; dbSNP:rs748989741).
FT                                {ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_064958.
FT   VARIANT     375    375       S -> F (in CN1; no enzyme activity;
FT                                dbSNP:rs72551353).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:1634050,
FT                                ECO:0000269|PubMed:7906695,
FT                                ECO:0000269|PubMed:7989595}.
FT                                /FTId=VAR_007705.
FT   VARIANT     376    376       H -> R (in CN1 and CN2).
FT                                /FTId=VAR_026144.
FT   VARIANT     377    377       G -> V (in CN1 and CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026145.
FT   VARIANT     381    381       S -> R (in CN1; dbSNP:rs72551354).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007706.
FT   VARIANT     387    387       P -> H (in CN2; has no residual bilirubin
FT                                glucuronidation activity).
FT                                {ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_064959.
FT   VARIANT     387    387       P -> S (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026146.
FT   VARIANT     395    395       G -> V (in CN1; has no residual bilirubin
FT                                glucuronidation activity;
FT                                dbSNP:rs367897068).
FT                                {ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:17229650,
FT                                ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_026147.
FT   VARIANT     400    400       N -> D (in CN2; dbSNP:rs28934877).
FT                                {ECO:0000269|PubMed:12402338}.
FT                                /FTId=VAR_019412.
FT   VARIANT     401    401       A -> P (in CN1; dbSNP:rs72551355).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007707.
FT   VARIANT     402    402       K -> T (in CN1; has no residual bilirubin
FT                                glucuronidation activity; N-glycosylation
FT                                does take place at this new additional
FT                                site). {ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_064960.
FT   VARIANT     403    403       R -> C (in CN2; dbSNP:rs778766461).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026148.
FT   VARIANT     428    428       K -> E (in CN1; dbSNP:rs72551356).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007708.
FT   VARIANT     443    443       L -> P (in CN2; has no residual bilirubin
FT                                glucuronidation activity;
FT                                dbSNP:rs758411577).
FT                                {ECO:0000269|PubMed:17229650,
FT                                ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_064961.
FT   VARIANT     461    461       W -> R (in CN1 and CN2).
FT                                {ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_026149.
FT   VARIANT     478    478       A -> D (in CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026150.
FT   VARIANT     486    486       Y -> D (in CN2, GILBS and HBLRTFN;
FT                                displays less than 10% of wild-type
FT                                bilirubin glucuronidation activity;
FT                                dbSNP:rs34993780).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:11061796,
FT                                ECO:0000269|PubMed:18004206,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:8280139,
FT                                ECO:0000269|PubMed:9621515,
FT                                ECO:0000269|PubMed:9627603}.
FT                                /FTId=VAR_007709.
FT   VARIANT     511    511       A -> P (in dbSNP:rs1042709).
FT                                /FTId=VAR_025355.
SQ   SEQUENCE   533 AA;  59591 MW;  19C90231AD0EB547 CRC64;
     MAVESQGGRP LVLGLLLCVL GPVVSHAGKI LLIPVDGSHW LSMLGAIQQL QQRGHEIVVL
     APDASLYIRD GAFYTLKTYP VPFQREDVKE SFVSLGHNVF ENDSFLQRVI KTYKKIKKDS
     AMLLSGCSHL LHNKELMASL AESSFDVMLT DPFLPCSPIV AQYLSLPTVF FLHALPCSLE
     FEATQCPNPF SYVPRPLSSH SDHMTFLQRV KNMLIAFSQN FLCDVVYSPY ATLASEFLQR
     EVTVQDLLSS ASVWLFRSDF VKDYPRPIMP NMVFVGGINC LHQNPLSQEF EAYINASGEH
     GIVVFSLGSM VSEIPEKKAM AIADALGKIP QTVLWRYTGT RPSNLANNTI LVKWLPQNDL
     LGHPMTRAFI THAGSHGVYE SICNGVPMVM MPLFGDQMDN AKRMETKGAG VTLNVLEMTS
     EDLENALKAV INDKSYKENI MRLSSLHKDR PVEPLDLAVF WVEFVMRHKG APHLRPAAHD
     LTWYQYHSLD VIGFLLAVVL TVAFITFKCC AYGYRKCLGK KGRVKKAHKS KTH
//
